Has VZV epidemiology changed in Italy? Results of a seroprevalence study by De Donno A. et al.
RESEARCH PAPER
Has VZV epidemiology changed in Italy? Results of a seroprevalence study
Antonella De Donnoa, Parvane Kuhdarib, Marcello Guidoa, Maria Cristina Rotac, Antonino Bellac, Giordana Brignoled,
Silvia Lupi b, Adele Idoloa, Armando Stefanati b, Martina Del Mansoc, Giovanni Gabuttib, and
The Study Group on seroepidemiology#
aUniversity of Salento, Lecce, Italy; bUniversity of Ferrara, Ferrara, Italy; cIstituto Superiore di Sanita, Rome, Italy; dLocal Health Unit 4 “Chiavarese,"
Liguria Region, Italy
ABSTRACT
The aim of the study was to evaluate if and how varicella prevalence has changed in Italy. In particular a
seroprevalence study was performed, comparing it to similar surveys conducted in pre-immunization era.
During 2013–2014, sera obtained from blood samples taken for diagnostic purposes or routine investigations
were collected in collaboration with at least one laboratory/center for each region, following the approval of
the Ethics Committee. Data were stratiﬁed by sex and age. All samples were processed in a national reference
laboratory by an immunoassay with high sensitivity and speciﬁcity. Statutory notiﬁcations, national hospital
discharge database and mortality data related to VZV infection were analyzed as well. A total of 3707 sera
were collected and tested. In the studied period both incidence and hospitalization rates decreased and about
5 deaths per year have been registered. The seroprevalence decreased in the ﬁrst year of life in subjects
passively protected by their mother, followed by an increase in the following age classes. The overall antibody
prevalence was 84%. The comparison with surveys conducted with the samemethodology in 1996–1997 and
2003–2004 showed signiﬁcant differences in age groups 1–19 y. The study conﬁrms that in Italy VZV infection
typically occurs in children. The impact of varicella on Italian population is changing. The comparison between
studies performed in different periods shows a signiﬁcant increase of seropositivity in age class 1 – 4 years,
expression of vaccine interventions already adopted in some regions.
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Introduction
Worldwide, varicella (chickenpox) is an endemic, highly conta-
gious, disease caused by a Herpesvirus called varicella-zoster
virus (VZV).1 In temperate climates, at least 90% of the popula-
tion acquires the disease within 15 y of age (95% in adult-
hood).2 In tropical countries, chickenpox has a lower
incidence; primary infection is less frequent in children and
mainly involves adult age groups, as a result of climatic factors
that play a role in inﬂuencing the spreading of the virus.3 Pri-
mary infection usually elicits a long lasting immune response
which, anyway, cannot avoid neither virus’ latency nor its sub-
sequent reactivation after many years. Virus’ reactivation is
linked to a decrease of VZV-speciﬁc cell-mediated response.4
From the clinical point of view, varicella is often considered
a benign disease. However, in 2–6% of cases some complica-
tions can occur. These latter are classiﬁed as infectious (cutane-
ous and soft tissue super-infections, bacterial pneumonia, etc.),
neurological (cerebellitis, encephalitis, meningitis, etc.) and
haematological (anemia, thrombocytopenic autoimmune pur-
pura, etc.).5
The majority of complications and hospitalizations due to
chickenpox occurs in immunologically healthy children without
any co-morbidity.6 However, the severity of primary infection
tends to increase with the age of the patient; the most severe clin-
ical manifestations of the disease involve teenagers, adults and
immunocompromised patients.7 Several European studies show
an incidence of hospitalization ranging between 1.3 and 4.5 for
100,000 inhabitants/year and 12.9–28.0/100,000 children 16 y
of age/year, with an average length of stay ranging from 3 to 8 d.8
VZV infection in a susceptible pregnant woman is particu-
larly worrying. The incidence of VZV in pregnancy is estimated
equal to 1–7/10,000 pregnancies.9 The virus acquired during
the last trimester may result in an increased risk of pneumonia
for the pregnant woman. Besides, VZV may infect the fetus or
the newborn during the intrauterine stage (congenital infec-
tion), during labor (perinatal infection) or after birth (postnatal
infection). The vertical transmission of the pathogen can imply
fetal death, abortion, premature birth, intrauterine growth
retardation, and different defects, already evident at birth or,
more frequently, occurring as sequelae.10
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Nowadays, chickenpox is the most widespread vaccine-pre-
ventable infectious disease. In industrialized countries with
temperate climate, VZV infection in the absence of vaccination
is acquired by more than 90% of subjects before adolescence
and less than 5% of adults remains susceptible.11 This means
that each year the number of new cases approximates that of a
birth cohort. According to the World Health Organization
(WHO), the worldwide burden of varicella is estimated to be
approximately 140 million cases with 4,200,000 severe compli-
cations that require hospitalization and 4200 deaths.12
Surveillance systems in different European countries are very
heterogeneous and sometimes absent; for these reasons, underes-
timation of cases is considerable. VZV spreads widely in Europe
and in most countries the infection is acquired between 2 and
10 y of age, as demonstrated by seroprevalence studies.5 The dif-
ferent social and educational structure of each country could
explain differences, even signiﬁcant, in the spread of the virus.13
As a result of the healthcare and economic impact of vari-
cella, many countries have introduced immunization in
infancy, using commercially available vaccines (monovalent
varicella (V) or quadrivalent Measles-Mumps-Rubella-Vari-
cella (MMRV)). All varicella vaccines are effective, safe and
imply high seroconversion rates (about 90% and 99% of immu-
nized children develop a virus-speciﬁc protective antibody titer
after the ﬁrst and second dose, respectively).12 Accordingly to
the National Vaccination Plan (PNPV) 2012–2014, in Italy uni-
versal vaccination for varicella should have been adopted in all
regions in 2015 starting from the 2014 birth cohort.14 Notewor-
thy, due to the decentralization of the Italian Health Service,
since many years 8 regions (so called “pilot” regions) already
started universal varicella vaccination (UVI), administering 2
doses of vaccine, the ﬁrst at 13–15 months of age and the sec-
ond one at 5–6 y of age.
The European Center for Disease Prevention and Control
(ECDC) recently published a document on varicella vaccination
in Europe recommending to implement epidemiological surveil-
lance. Seroepidemiological surveys are indicated as an appropri-
ate method to monitor both the spreading of the pathogen and
the impact of already implemented vaccine strategies.5
The current seroepidemiological study aims, beside to update
the knowledge on the spreading of the virus in Italy, to verify if
and what changes have occurred over the years, taking account
of similar surveys previously performed. Besides, an overview of
the national burden of varicella has been evaluated taking into
account data of already implemented surveillance systems.
Methods
A national cross-sectional population-based seroprevalence
study of varicella antibodies was conducted.
The study was approved by the Ethics Committee of the Isti-
tuto Superiore di Sanita (ISS) in compliance with current
regulations on the protection of personal data.15 Anonymous
unlinked samples of residual sera from routine laboratory test-
ing, provided by a reference laboratory in each region, were col-
lected. Samples from individuals known to have an
immunosuppressive or acute infectious disease and those from
individuals who had recently undergone a blood transfusion
were excluded. All individuals who provided serum samples
gave verbal informed consent; consent for minors was provided
by parents or legal guardians.
The number of sera to be collected for each age group
(Table 1) was calculated using estimated antibody prevalence
in that age-group obtained from a previous serology study. A
minimum number of 3275 serum samples, equally distributed
by gender, were to be collected.
Sera were stored at ¡20C until tested by the laboratory of
the University of Salento, Lecce, for varicella antibodies. Anti-
VZV speciﬁc antibodies were detected using a commercially
available enzyme linked immunoassay (ELISA) (Enzygnost
anti-VZV/IgG, Siemens HealthCare Diagnostics GmbH),
which according to the manufacturer has a sensitivity of 99.3%
and a speciﬁcity of 100%. Sera were classiﬁed as negative if the
optical density (OD) was less than 0.100 and as positive if
higher than 0.200; sera with an OD reproducibly between 0.100
and 0.200 were classiﬁed as equivocal. The antibody status,
expressed in mIU/ml, was based on the WHO International
Standard for Varicella-Zoster Immunoglobulin (50 interna-
tional units, IU).
Data were summarized as frequencies and positive antibody
titres presented as geometric means along with their respective
95% conﬁdence intervals (CI). Data were stratiﬁed by age, gen-
der and geographic area. Differences among percentages of
seropositive subjects were evaluated by Chi-square test while
differences among geometric mean titers (GMTs) were per-
formed using Student t-test on previously logarithmically trans-
formed antibody titres. All statistical analysis were performed
by Stata software version 11.2 (Stata Corporation, College Sta-
tion, Texas, USA).
Varicella statutory notiﬁcations and national hospital dis-
charge database for the period 2000–2014 were also analyzed.
Varicella mortality data for the years 2001–2003 and 2006–
2012 were obtained from the ISTAT database of the causes of
mortality (data for the years 2004 and 2005 has never been
released at national level).
Results
Overall, 3707 samples were collected (from January 2013 to
December 2014) and analyzed; 3058 were positive and 583 neg-
ative. The remaining 66 sera, conﬁrmed as equivocal, were
excluded from the analysis. Seroprevalence showed a typical
trend with a decrease in the ﬁrst year of life in subjects ﬁrst pas-
sively protected by their mother; then it increased in the
Table 1. Estimated number of sera to collect per age-group.
Age group (years) Age Bands Expected seroprevalence Precision of estimate Sample size Total sample size
0–19 1 y age bands 53% 10% 96 per 1 y interval 1920
20–39 5 y age bands 91% 4% 197 per 5 y interval 788
>40 10 y age bands 98% 2% 189 per 10 y interval 567
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following age classes (0–11 months: 47.2%; 1 year-old: 25.8%;
2–4 years: 47.0%; 5–9 years: 75.3%; 10–14 years: 89.4%;
15–19 years: 89.8%; 20–39 years: 93.2% and >40 years: 98.4%).
Overall seroprevalence was equal to 84.0%, without any statisti-
cally signiﬁcant difference by gender (p D 0.473); however, it
showed a signiﬁcant difference among the 3 Italian geographic
areas (North 84.9%, Center 87.3%, and South 80.6%;
p < 0.001). Anyway, signiﬁcant differences were observed only
in some age groups: in the age class 2–4 y seroprevalence was
lower in Northern and Central Italy than in Southern Italy
(p D 0.0003), while it was higher than in Southern Italy in the
age groups 10–14 (p D 0.0001), 15–19 (p D 0.017) and 20–39 y
of age (p D 0.005) (Fig. 1).
A signiﬁcant increase in titres was observed when compar-
ing consecutive age-groups GMTs from 1 y to 14 y of age
(1 y vs 2–4 years: p D 0.011; 2–4 y vs 5–9 years: p < 0.001;
5–9 y vs 10–14 years: p < 0.015), while comparison in other
age groups were not signiﬁcantly different (except for 20–39 y
vs >40 years: p D 0.0002). No differences in GMTs were
detected between males and females. Signiﬁcant differences
were detected among geographic areas, being GMTs lower in
Southern Italy (p < 0.001).
Comparing overall seroprevalence observed in regions that
have not yet implemented (or have done it very recently) uni-
versal varicella immunization with seroprevalence found in the
8 “pilot” regions (Sicily, Apulia, Veneto, Tuscany, Calabria, Sar-
dinia, Basilicata, Autonomous Province of Bolzano) that have
adopted immunization since some years, no statistically signiﬁ-
cant difference was detected (p D 0.853). However, seropreva-
lence was signiﬁcantly higher in the age classes from 1 y to
2–4 y (1 year: p D 0.045; 2–4 years: p D 0.0009;) in the “pilot”
regions that ﬁrst introduced universal varicella immunization,
while in 5–9 and 10–14 y age groups, seroprevalence was signif-
icantly higher in the remaining regions (5–9 years: p D 0.023
and 10–14 years: p < 0.0001) (Fig. 2).
In 2013–2014 study overall seroprevalence (84.0%) was
higher than those observed in 2 previous studies performed
with the same methodology in 1996–1997 (73.2%) and 2003–
2004 (77.8%) (Fig. 3).16,17 More in detail, seroprevalence
observed in the present study was signiﬁcantly greater in com-
parison to the ones previously observed in the age classes from
1 to 15–19 y of age. Starting from the 20–39 age class, no statis-
tically signiﬁcant differences were detected among the 3 studies.
The implementation of UVI in some regions had probably
an impact on national epidemiology. The average annual num-
ber of cases in Italy, in the period 2003–2015, was equal to
72,854 cases (range: 34,955–123,264) with an average annual
incidence of 129.4 cases per 100,000 population. The annual
incidence rate reached a peak in 2004 with an incidence of
214.4 (per 100,000 population) and then steadily declined,
reaching 77.3 (per 100,000 population) in 2014.
Overall, in the period 2001–2014, 24,192 hospitalizations for
varicella were observed. The mean annual number of hospitaliza-
tions in Italy was 1,728 (range: 1,126–2,397) and the average annual
incidence was 3 per 100,000 population, with a decreasing trend
very similar to that shown by statutory notiﬁcations. Incidence of
hospitalizations reached a maximum of 4.2 per 100,000 in 2002
and 2004 and aminimum of 1.9 per 100,000 in 2013 and 2014.
About 70% of the total hospitalizations due to varicella
involved children (0–14 age group). Hospitalization rate was
42.9 per 100,000 population in children under one year of age,
26.6 in the 1–4 age group and 6.8 in the 5–14 age group. Mor-
tality data showed an average of 4 and 6 deaths in the periods
2001–2010 and 2011–2012, respectively.
Discussion
Universal vaccination against varicella, already adopted in
many countries during childhood with the administration of 2
doses, allows to achieve signiﬁcant results in terms of reduction
Figure 1. VZV seroprevalence stratiﬁed by age class and geographical area, Italy 2013–2014.
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of the virus spreading, impact on complications and hospital-
izations, protection of high-risk subjects and disease related
costs’ savings.18
Essential prerequisite for the achievement of positive results
is the early attainment and maintenance of high vaccine cover-
age rates to avoid indirect effects (such as the increase of the
mean average age of infection and a higher risk of serious com-
plications in older susceptible subjects that become infected).19
In Italy varicella has been and still is the most relevant vac-
cine preventable infectious disease. For many years, notwith-
standing the availability of vaccines, varicella immunization
has not been recommended nor implemented at national level.
The last and still ongoing National Immunization Plan 2012–
2014 did not include universal varicella immunization and
provided vaccination for anamnestically negative and unimmu-
nized subjects with a 2-dose schedule. Interestingly, the same
National Plan says that universal vaccination for chickenpox
should have been adopted in all regions in 2015 starting from
the 2014 birth cohort.14 Anyway, even if the immunization for
chickenpox was not planned at national level until 2015, start-
ing from 2003, 8 regions (“pilot” regions) out of 21, have pro-
gressively offered universal varicella vaccination, administering
2 doses of vaccine in children aged 13–15 months and 5–6 y
respectively. Despite the limitations of passive surveillance
Figure 3. Comparison between VZV seroprevalence stratiﬁed by age class, Italy 1996–1997, 2003–2004 and 2013–2014.
Figure 2. VZV seroprevalence in Italy, 2013–2014. Comparison between “pilot” vs “not pilot” Regions.
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systems, the nationwide trend of notiﬁcations and hospitaliza-
tions from 2005 showed a progressive decrease that could be at
least partly related to the impact of vaccine interventions imple-
mented in the above mentioned regions.20,21
The effectiveness of immunization has also been demon-
strated in a previous research where the changes in the seroepi-
demiological pattern were assessed in the same 8 “pilot”
regions. The increase in seroprevalence was most evident in the
age groups target of immunization.22
The data of the present study conﬁrm that the impact of var-
icella on Italian population is changing. As a matter of fact, in
comparison to data obtained in 1996–1997 and 2003–2004 the
rate of seropositivity signiﬁcantly increased in the age groups 1
and 2–4 y highlighting the crucial role played by immunization
interventions already implemented in 8 “pilot” regions which,
in terms of residents, represent the 37.2% of the Italian popula-
tion. In the age group 5–19 y seroprevalence was higher in the
remaining regions probably because of high circulation of vari-
cella virus in absence of universal immunization strategy.22
We must consider that the “late adopters” regions (that is,
regions that have not yet started UVI) account for about 1/2 of
Italian population. For this reason the active offer of varicella
vaccine in all Italian regions and the catch up programmes for
susceptible cohorts should be encouraged.
The continuous updating of epidemiological data, both in terms
of disease impact (notiﬁcation of cases, complications, hospitaliza-
tions, and deaths) as well as seroprevalence changes due to pro-
gram implementation of immunization strategies, is crucial for the
overall assessment of the impact of vaccination against chickenpox.
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